Abstract:Ruthenium(II/III) coordination compounds have gained widespread attention as chemotherapy drugs, photosensitizers, and photodynamic therapy reagents. Herein, a family of 11 novel coumarin-coordinated 8-hydroxyquinoline ruthenium(II/III) compounds, i.e., [RuII2(μ2-Cl)2(QL1a)2(DMSO)4] (YNU-4a = Yulin Normal University-4a), [RuII2(μ2-Cl)2(QL1b)2(DMSO)4] (YNU-4b), [RuII2(μ2-Cl)2(QL1c)2(DMSO)4] (YNU-4c), [RuII2(μ2-Cl)2(QL1d)2(DMSO)4]⋅2CH3OH (YNU-4d), [RuII(QL1e)2(DMSO)2] (YNU-4e), [RuIII(QL1e)2(QL3a)] (YNU-4f), [RuIII(QL1e)2(QL3b)] (YNU-4g), [RuIII(QL1e)2(QL3c)] (YNU-4h), [RuIICl2(H-QL3a)2(DMSO)2] (YNU-4i), [RuIICl2(H-QL3b)2(DMSO)2] (YNU-4j), and [RuIICl2(H-QL3c)2(DMSO)2] (YNU-4k), featuring the coligands 5,7-diiodo-8-hydroxyquinoline (H-QL1a), 5,7-dichloro-8-quinolinol (H-QL1b), 5-chloro-7-iodo-8-hydroxyquinolin (H-QL1c), 5,7-dibromo-8-hydroxyquinoline (H-QL1d), and 5,7-dichloro-8-hydroxy-2-methylquinoline (H-QL1e) and the main ligands 6,7-dichloro-3-pyridin-2-yl-chromen-2-one (H-QL3a), 6-bromo-3-pyridin-2-yl-chromen-2-one (H-QL3b), and 6-chloro-3-pyridin-2-yl-chromen-2-one (H-QL3c), respectively. The structure of compounds YNU-4a-YNU-4k was fully confirmed by conducting various spectroscopic analyses. The anticancer activity of YNU-4a-YNU-4k was evaluated in cisplatin-resistant A549/DDP lung cancer cells (LC549) versus normal embryonic kidney (HEK293) cells. Notably, compound YNU-4f bearing QL1e and QL3a ligands showed a more pronounced antiproliferative effect against LC549 cells (IC50 = 1.75 ± 0.09 μM) with high intrinsic selectivity toward LC549 cancer cells than YNU-4a-YNU-4e, H-QL1a-H-QL1e, cisplatin (PDD), YNU-4g-YNU-4k, and H-QL3a-H-QL3c. Additionally, a colocalization assay analysis of YNU-4e and YNU-4f showed that these two ruthenium(II/III) compounds were subcellularly accumulated in the mitochondria and other regions of the cytoplasm, where they induce mitophagy, adenosine triphosphate (ATP) reduction, mitochondrial respiratory chain complex I/IV(RC1/RC4) inhibition, and mitochondrial dysfunction. Accordingly, compounds YNU-4a-YNU-4k can be regarded as mitophagy inductors for the eradication of cisplatin-resistant LC549 cancer cells.

Complexation with Organometallic Ruthenium Pharmacophores Enhances the Ability of 4-Anilinoquinazolines Inducing Apoptosis

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands

Discovery Of A Dual-Targeting Organometallic Ruthenium Complex With High Activity Inducing Early Stage Apoptosis Of Cancer Cells

Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines

Novel Ruthenium Complexes Ligated with 4-Anilinoquinazoline Derivatives: Synthesis, Characterisation and Preliminary Evaluation of Biological Activity.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.

Insights into the antineoplastic activity and mechanisms of action of coumarin-coordinated 8-hydroxyquinoline ruthenium(II/III) compounds

Ruthenium Complexes with Phenylterpyridine Derivatives Target Cell Membrane and Trigger Death Receptors-Mediated Apoptosis in Cancer Cells.

Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-dihydroxypropyl)-formamide Oxoaporphine (FOA): in Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell Apoptosis.

Ruthenium(II) Polypyridyl Complexes: Cellular Uptake, Cell Image and Apoptosis of HeLa Cancer Cells Induced by Double Targets

Ruthenium Complexes Containing Bis-Benzimidazole Derivatives As a New Class of Apoptosis Inducers.

The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes.

Ruthenium(II) Polypyridyl Complexes with Visible Light-Enhanced Anticancer Activity and Multimodal Cell Imaging.

Ruthenium–Porphyrin Complexes Induce Apoptosis by Inhibiting the Generation of Intracellular Reactive Oxygen Species in the Human Hepatoma Cell Line (Hepg2)

Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes

Antitumor studies evaluation of triphenylphosphine ruthenium complexes with 5,7-dihalo-substituted-8-quinolinoline targeting mitophagy pathways

Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex

Ruthenium (ii) Polypyridyl Complexes Stabilize the Bcl-2 Promoter Quadruplex and Induce Apoptosis of Hela Tumor Cells

Antitumor Activity of Iridium/ruthenium Complexes Containing Nitro -Substituted Quinoline Ligands in Vivo and in Vitro

Stabilization of Telomere DNA, and Mechanism of Apoptosis of Tumor Cells Induced by Ruthenium Complexes